|Videos|December 22, 2019
Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03
Author(s)Sponsored Content
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Updates Safety Warnings for Common Chemotherapy Drugs
2
New Combination Treatment Approach Studied in Pancreatic Cancer
3
KTX-1001 Elicits Responses in Some With Multiple Myeloma
4
Biomarker-Free Relacorilant Combo Broadens Options in Ovarian Cancer
5